# Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

> **NCT01732926** · PHASE3 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 475 (actual)

## Conditions studied

- Indolent Non-Hodgkin's Lymphomas

## Interventions

- **DRUG:** Idelalisib
- **DRUG:** Rituximab
- **DRUG:** Bendamustine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01732926
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-01-02
- **Primary completion:** 2016-05-17
- **Final completion:** 2016-05-17
- **Target enrollment:** 475 (ACTUAL)
- **Last updated:** 2018-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01732926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01732926, "Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT01732926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*